Protocol Ledger

NCT04205812 · Phase III · COMPLETED

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT04205812 sponsored by Incyte in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-11 Enrollment: 583 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04205812
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)583 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04205812
Protocol FieldVerified Registry Value
NCT IdentifierNCT04205812
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment583 participants (ACTUAL)
Registered Start Date2020-09-11
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI